Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4MSLY)

Drug Name

ZN-c3 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Uterine serous carcinoma	2C72.1	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Wee1-like protein kinase (WEE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-1775	DM3WDZ5	Ovarian cancer	2C73	Phase 2	[3]
9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione	DMGCX7E	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04814108) A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
3	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
4	Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur J Med Chem. 2009 Apr;44(4):1383-95.